In the present study, the TMSC injection group showed improvements in severity of colitis, weight loss, and colon length compared to the control group, and levels of proinflammatory cytokines including IL-1β and IL-6 were low, similar to the results of previous studies which assessed the effect of MSC. This evidence concerns the gene IL1B and colitis.